Clinical trial NCT04090853: Subject Evaluation of a 1064nm Diode Laser/RF
Official title: Subject Evaluation of the Efficacy of a 1064 nm Diode Laser, Pulsed Electro-Magnetic Fields and Vacuum Assisted Multipolar Radio Frequency for Non-invasive Contouring of the Abdomen and Flanks
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Subcutaneous Fat Disorder
Lead sponsor: Venus Concept
Sponsor class: INDUSTRY
First posted: 2019-09-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single group assessed patient feedback regarding satisfaction post treatment
Primary purpose: TREATMENT

Brief summary: Open-label, baseline-controlled, multi-center study evaluating a 1064 nm diode laser, pulsed electromagnetic fields and vacuum assisted radio frequency for non-invasive fat reduction of the abdomen and flanks.

Detailed description: The study will enroll up to 200 subjects requesting non-invasive lipolysis of the abdomen and flanks. Each subject will receive up to 3 study treatments of the diode laser and up to 3 treatments of the pulsed electromagnetic fields and vacuum assisted radio frequency study treatments. Subjects will be followed at 24 weeks post diode treatments to observe their satisfaction with treatment outcomes.

Eligibility criteria: Inclusion Criteria:

1. Able to read, understand and voluntarily provide written informed consent.
2. Healthy male or female, ≥ 18 years of age seeking treatment for unwanted fat in the flanks and or abdomen
3. BMI score is less than 35.
4. Able and willing to comply with the treatment/follow-up schedule and requirements.
5. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.

Exclusion Criteria:

1. Pregnant, intending to become pregnant, postpartum or nursing in the last 6 months.
2. Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
3. History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications, 6 months prior to and during the course of the study.
4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
5. Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment.
6. Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
7. Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate).
8. Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder.
9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
10. Tattoos in the treatment area.
11. Poor skin quality (severe laxity).
12. Abdominal wall, muscular abnormality or hernia on physical examination.
13. Use of retinoids such as oral isotretinoin (Accutane™) within the past six months or during course of the study.
14. History of keloid or hypertrophic scar formation or poor wound healing in the treatment area.
15. As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate.
16. Unable or unlikely to refrain from sun exposure, artificial tanning, including the use of tanning booths, prior to (six weeks) and during the course of the evaluation.

Primary outcomes:
measure: Patient Overall Satisfaction
timeFrame: Week 26
measure: Patient Treatment Satisfaction
timeFrame: Week 26
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Shah Aesthetic Surgery
state: Colorado
city: Foxboro
country: United States
facility: Medical Management Solutions INC
state: Massachusetts
city: Woodmere
country: United States
facility: SRS Dermatology
state: New York
Study officials:
affiliation: Venus Concept LTD
name: Yoni Iger
role: STUDY_DIRECTOR
References: